MIRA Pharmaceuticals, Inc. (MIRA) NASDAQ
1.03
-0.02(-1.90%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
1.03
-0.02(-1.90%)
Currency In USD
Address
855 North Wolfe Street
Baltimore, MD 21205
United States of America (the)
Phone
737-289-0835
Sector
Healthcare
Industry
Drug Manufacturers - General
Employees
2
First IPO Date
August 14, 2023
| Name | Title | Pay | Year Born |
| Erez Aminov | Chief Executive Officer & Chairman | 700,682 | 1979 |
| Alan Weichselbaum | CFO & Treasurer | 59,829 | 1965 |
| Itzchak Angel | Chief Scientific Advisor | 0 | N/A |
MIRA Pharmaceuticals, Inc. operates as a clinical development stage biopharmaceutical company. The company focuses on the development and commercialization of a new molecular synthetic tetrahydrocannabinol (THC) analog under investigation for the treatment of adult patients with anxiety and cognitive decline typically associated with early-stage dementia. It is developing MIRA1a, a synthetic cannabinoid analog to treat anxiety and chronic pain by targeting the cannabinoid type 1 and type 2 receptors. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Baltimore, Maryland.